Wall Street analysts tracking Anavex Life Sciences have established a consensus twelve-month average price target that sits significantly higher than its current market valuation, implying a substantial theoretical percentage upside according to recent tracking data. Individual analyst targets range across a spread of minimum and maximum figures, reflecting varying degrees of optimism regarding the clinical approval trajectory of their lead neurodegenerative drug candidates. These consensus targets are recalculated periodically by financial data aggregators based on the most recent research reports, rating adjustments, and target revisions issued by covering brokerage firms. Investors should keep in mind that analyst price targets represent speculative projections rather than guaranteed financial outcomes, and clinical-stage biotechnology targets often experience dramatic downward or upward revisions following major trial results.